Themis Medicare Ltd has informed BSE that the Company have for the First Time entered into an altogether new pharmaceutical marketing segment - COSMETO - DERMATOLOGY with the launch of the brand LUMIXYL.
LUMIXYL incorporates a new technology called Peptide that addresses a skin disorder called Hyper-pigmentation i.e., darkening of skin. The product is being introduced in India through the Company's new Division 'LUMINOUS' that has been launched for this very range of products.
Themis Medicare is the First and Only Company to market LUMIXYL in India.
LUMIXYL incorporates a new technology called Peptide that addresses a skin disorder called Hyper-pigmentation i.e., darkening of skin. The product is being introduced in India through the Company's new Division 'LUMINOUS' that has been launched for this very range of products.
Themis Medicare is the First and Only Company to market LUMIXYL in India.
No comments:
Post a Comment